Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to ... pointing to yet another potential use for the versatile drug class. The small, 48-subject study – published in the journal ...

Existing interventions often address withdrawal symptoms or the “high” associated with drug use, leaving underlying compulsive behaviors unaddressed. GLP-1 agonists could fill this gap by ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug for weight management. The Food and Drug Administration’s approval ...

New evidence regarding the additional benefits (besides weight loss) and risks of glucagon-like peptide-1 (GLP-1) receptor agonists from ... suggest that GLP-1 drugs compared to other diabetes ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated ... about the short-term safety of these drugs,” the authors write. “Nevertheless, evidence was ...

Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared nearly 600% between 2020 and 2023 in people ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced ... interstitial nephritis, and drug-induced pancreatitis ...